EUVIMEDEUVIMED entdecken
Crossref

Exploration of New Dihydroindazole Derivatives as Promising Anti‐TB Agents: Design, Synthesis, In Silico, and Biological Evaluation

Pardeep Kumar, Pradip Malik, Juned Ali, Deepanshi Saxena, Anuradha Singampalli, Bandela Rani, Sri Mounika Bellapukonda, Ankita Devi, Nagesh A Bhale, Amol G Dikundwar iD, Srinivas Nanduri iD, Arunava Dasgupta und 2 weitere

Archiv der Pharmazie · 2025-08 · 358 (8)

DOI: 10.1002/ardp.70074 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, online erschienen am 15.08.2025. Verfasst von Pardeep Kumar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India. Hauptthemen laut MEDLINE: Antitubercular Agents, Mycobacterium tuberculosis, Drug Design, Indazoles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The escalating threat of drug‐resistant Mycobacterium tuberculosis ( Mtb ) necessitates the discovery of novel chemotherapeutic agents. In this study, a series of dihydroindazole‐based derivatives were designed, synthesized, and evaluated for their antimycobacterial potential. Among the synthesized compounds, 8u exhibited the most potent in vitro activity against Mtb H 37 Rv with a minimum inhibitory concentration (MIC) of 2 µg/mL, while 8i and 8q showed moderate activity (MIC = 8 µg/mL). Several analogs demonstrated MICs in the range of 16–32 µg/mL. 8u also displayed enhanced activity against single‐drug‐resistant Mtb strains, outperforming ethambutol and rifampicin. Structure–activity relationship analysis indicated that both the hydrazide linker and heteroaryl substitutions significantly influenced antimycobacterial activity. 8u was non‐cytotoxic to Vero cells (CC₅₀ > 100 µg/mL), yielding a selectivity index (SI) > 50. Time–kill kinetics confirmed its bactericidal nature. Mechanistic investigations using molecular docking and 100‐ns molecular dynamics simulations identified InhA as the probable molecular target. In silico ADMET predictions (QikProp and ProTox‐3.0) supported favorable pharmacokinetic and toxicity profiles. Collectively, these findings highlight 8u as a promising lead for the development of next‐generation anti‐TB agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antitubercular AgentsMycobacterium tuberculosisDrug DesignIndazolesMicrobial Sensitivity TestsStructure-Activity RelationshipVero CellsChlorocebus aethiopsAnimalsMolecular Docking SimulationMolecular StructureMolecular Dynamics SimulationDose-Response Relationship, Drug

Stichwörter der Autor:innen

InhA inhibitorsQSARdihydro‐indazolemolecular dynamics simulationmulti‐drug resistancetuberculosis

Substanzen

Antitubercular AgentsIndazoles

Autor:innen und Institutionen

  • Department of Chemical Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India.
  • Division of Molecular Microbiology and Immunology, CSIR-Central Drug Research Institute, Janakipuram Extension, Lucknow, Uttar Pradesh, India.
  • Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India.
  • Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Balanagar, Hyderabad, Telangana, India.
  • AcSIR: Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.

ORCID-Profile: Amol G Dikundwar, Srinivas Nanduri, Yaddanapudi Venkata Madhavi

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Kumar, P., Malik, P., Ali, J., Saxena, D., Singampalli, A., Rani, B., Bellapukonda, S. M., Devi, A., Bhale, N. A., Dikundwar, A. G., Nanduri, S., Dasgupta, A., Chopra, S., & Madhavi, Y. V. (2025). Exploration of New Dihydroindazole Derivatives as Promising Anti‐TB Agents: Design, Synthesis, In Silico, and Biological Evaluation. Archiv der Pharmazie, 358(8). https://doi.org/10.1002/ardp.70074

Vancouver

Kumar P, Malik P, Ali J, Saxena D, Singampalli A, Rani B, et al. Exploration of New Dihydroindazole Derivatives as Promising Anti‐TB Agents: Design, Synthesis, In Silico, and Biological Evaluation. Archiv der Pharmazie. 2025;358(8). doi:10.1002/ardp.70074

BibTeX
@article{Kumar2025,
  author = {Kumar, Pardeep and Malik, Pradip and Ali, Juned and Saxena, Deepanshi and Singampalli, Anuradha and Rani, Bandela and Bellapukonda, Sri Mounika and Devi, Ankita and Bhale, Nagesh A and Dikundwar, Amol G and Nanduri, Srinivas and Dasgupta, Arunava and Chopra, Sidharth and Madhavi, Yaddanapudi Venkata},
  title = {Exploration of New Dihydroindazole Derivatives as Promising Anti‐TB Agents: Design, Synthesis, In Silico, and Biological Evaluation},
  journal = {Archiv der Pharmazie},
  year = {2025},
  volume = {358},
  number = {8},
  doi = {10.1002/ardp.70074}
}
Kostenlos starten →